Assessing the safety of lumateperone in young patients with schizophrenia or bipolar disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, global trial evaluates the safety and tolerability of lumateperone in pediatric patients diagnosed with schizophrenia or bipolar disorder. The study includes a 26-week open-label treatment period where participants will receive lumateperone daily, following a screening phase to determine eligibility. Patients will be monitored for safety and tolerability, with a follow-up period to assess any adverse effects after treatment. The trial aims to gather important data on the use of lumateperone in younger populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able to provide consent as follows:

  * The patient's legally authorized representative (LAR) (eg, parent or guardian) must provide written, informed consent;
  * The patient must provide written assent to study enrollment;
* Male or female patients aged 13 to 17 years (inclusive) with schizophrenia; male or female patients aged 10 to 17 years (inclusive) with bipolar I or II disorder; or male or female patients aged 5 to 17 years (inclusive) with autism spectrum disorder;
* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of schizophrenia, bipolar I or II disorder, or autism spectrum disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL).
* Is currently an outpatient and is anticipated to maintain outpatient status for the duration of the study.

Rollover Patients entering from the lead-in study must have safely completed the lead-in study, in the opinion of the Investigator.

Exclusion Criteria:

* Has a primary psychiatric diagnosis other than schizophrenia, bipolar I or bipolar II disorder or autism spectrum disorder. Schizophrenia with catatonia, or bipolar disorder with psychotic features are not allowed. Exceptions include:

  * ADHD: If a subject is taking psychostimulant(s) for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to Screening. The treatment regimen should remain stable throughout the study. This must be confirmed by the Investigator and noted in the source records.
  * For ASD patients only, based on Investigator opinion and DSM-5 criteria, mild or moderate intellectual disability is allowed. Severe or profound intellectual disability is exclusionary.
* In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during their participation in the study or

  * At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit;
  * At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or
  * At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) of the CDRS-R (for bipolar disorder patients only); or
  * The patient is considered to be an imminent danger to him/herself or others.

Where it's running

• Southwest Autism Research and Resource Center
  Phoenix, Arizona, United States Recruiting
• Pillar Clinical Research, LLC
  Little Rock, Arkansas, United States Recruiting
• Advanced Research Center, Inc
  Anaheim, California, United States Recruiting
• National Institute Of Clinical Research
  Garden Grove, California, United States Recruiting
• Excell Research Inc
  Oceanside, California, United States Recruiting
• Inland Psychiatric Medical Group Inc
  Redlands, California, United States Recruiting

+15 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Compassion-focused therapy for reducing self-stigma in mental health disorders

  This study is testing whether Compassion Focused Therapy can help people with mental health disorders feel better about themselves and reduce feelings of shame.

  Recruiting University Hospital, Strasbourg, France · Bordeaux and 6 other locations · NCT05698589

• Cerebellar stimulation to improve cognitive function and mood

  This study is testing if a special brain stimulation can help improve thinking and mood in people with schizophrenia, autism, bipolar disorder, and Parkinson's disease.

  Recruiting University of Iowa · Iowa City, Iowa · NCT03217110

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Venous Tourniquet with Low-Dose Sugammadex vs Arterial Tourniquet for Seizure Monitoring During ECT

  40 patients undergoing ECT will have a venous tourniquet on one arm and an arterial tourniquet on the other to see which method better reveals motor seizures.

  Recruiting Medipol University · Istanbul · NCT07534475

• 7T MRI and visual perception markers for severe mood and psychotic disorders

  This project tests whether 7‑tesla MRI scans combined with visual perception tests can identify brain markers linked to diagnosis and treatment outcomes in adults with major depressive disorder, bipolar disorder, or schizophrenia.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07479758

• Emotional Eating, Sleep Quality, Mental State, and Metabolic Syndrome in Psychiatric Patients

  This study tests how mood, sleep, and emotional eating relate to metabolic syndrome in people with schizophrenia or bipolar disorder.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07411222

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.